top of page


Start Date:

August 2019

End Date:

May 2022


30 months




Title: EXtraintestinal Pathogenic Escherichia Coli Trial (EXPECT)

Design: EXPECT1 - prospective observational pilot study; EXPECT2- prospective epidemiological study

Primary Objective: to provide a large network for rapid evaluation of novel treatment strategies; to generate innovative trial designs to facilitate the registration of novel antibacterial agents; and to design and validate tests to support the diagnosis of patients, identify the most appropriate treatments, and monitor the patient’s response.

Secondary Objective(s): 

  • EXPECT-1: to assess success factors and barriers for a future Phase 3 randomized controlled trial, where the efficacy of a new vaccine to prevent invasive ExPEC disease will be tested in community-dwelling adults.

  • EXPECT-2: To estimate the O-serotype distribution of ExPEC isolated from hospitalized patients aged 60 and older with invasive ExPEC disease, and to evaluate the clinical case definition and risk factors.


University of Utrecht - NETHERLANDS (Coordinator) 

Arbeitsgemeinschaft für Osteosynthesefragen (AO) Documentation and Publishing Foundation Clinical Investigation and Documentation - SWITZERLAND

Astra-Zeneca - ITALY

IDIBAPS August Pi i Sunyer Biomedical Research Institute - SPAIN

Centre Hospitalier Régional Universitaire de Besançon - FRANCE

Centre Hospitalier de LIMOGES - FRANCE

Cliniques Universitaries San Luc - BELGIUM

Da Volterra - ITALY

Eberhard Karls Universität Tuebingen - GERMANY

Erasmus Universitair Medisch Centrum Rotterdam - NETHERLANDS

European Clinical Research Infrastructure Network - FRANCE

University of Zurich - SWITZERLAND

European Forum for Good Clinical Practice - BELGIUM

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - ITALY

Fundacion Privada Instituto de Salud Global Barcelona - SPAIN

GlaxoSmithKline - UK

Goethe University Frankfurt - GERMANY


Helmholtz Centre for Infection Research - GERMANY

Hôpitaux Universitaires de Genève - SWITZERLAND

INSERM Institut National de la Santé Et de la Recherche Médicale - FRANCE

Instituto Nacional De Saùde - PORTUGAL

Janssen Infectious Diseases –Diagnostics

Julius Center Research Program Infectious Diseases - NETHERLANDS

Lausanne University Hospital - SWITZERLAND

Linköping Universitet - SWEDEN

Medical Center –University of Freiburg - GERMANY

North Bristol National Health Service Trust - UK

Radboud University Nijmegen Medical Centre - NETHERLANDS

Servicio Andaluz de Salud - SPAIN

Servicio Madrileño de Salud - SPAIN

Tel-Aviv Sourasky Medical Center - ISRAEL

The Medicines Company Rempex

University Hospital of Cologne - GERMANY

University Medicine of the Ernst Moritz Arndt - GERMANY

University of Antwerp - BELGIUM

University of Athens Medical School - GREECE

University of Greifswald - Germany

University of Oxford - UK

University of Verona - ITALY

Université Claude Bernard Lyon 1 - FRANCE

Université Joseph Fourier - FRANCE





Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study

Clinical Microbiology and Infection


Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)

Clinical Microbiology and Infection


Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases

ID-CARE Participants

Evelina Tacconelli


Gaia Maccarrone

Clinical Research Assistant

Elda Righi

Associate Professor

Ruth Joanna Davis

Project Officer

Anna Maria Azzini

Lecturer and Consultant Physician

From our Blog
In the News
bottom of page